Last edition
News about "Neurocrine Biosciences"
Neurocrine Initiates First-in-Human Trial for Novel Obesity Therapy NBIP-2118
Neurocrine launches phase I trial of NBIP-2118, a novel CRF2 agonist aimed at delivering fat-specific weight loss while preserving muscle in obesity treatment.
Neurocrine Biosciences | 05/05/2026 | By News Bureau
Neurocrine Biosciences to Acquire Soleno Therapeutics in USD 2.9 Billion Deal
The acquisition brings first-in-class Prader-Willi syndrome therapy VYKAT XR into Neurocrine’s portfolio, strengthening its position in endocrinology and rare diseases.
Neurocrine Biosciences | 07/04/2026 | By News Bureau
Neurocrine to Acquire Soleno Therapeutics
Neurocrine to acquire Soleno Therapeutics, adding US FDA-approved VYKAT XR for Prader-Willi Syndrome and strengthening its rare disease and endocrinology portfolio.
Neurocrine Biosciences | 07/04/2026 | By News Bureau
Dr. Sanjay Keswani to Lead Medical Strategy at Neurocrine Biosciences as New CMO
Dr. Keswani, who has more than 20 years of pharmaceutical industry experience with broad R&D expertise in multiple therapeutic areas, will lead the clinical development and medical affairs activities at Neurocrine.
Neurocrine Biosciences | 05/04/2025 | By Abha | 394
Neurocrine Biosciences Secures FDA Approval of CRENESSITY
CRENESSITY, a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist, is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone (ACTH) and downstream adrenal androgen production, allowing for glucocorticoid dose reduction.
Neurocrine Biosciences | 16/12/2024 | By Aishwarya | 208
Nxera Pharma to Get USD 35 Million from Neurocrine for Phase 2 Trial with NBI- '568
The NBI-’568-SCZ2028 dose-finding study met its primary endpoint for the once-daily 20 mg dose and was generally safe and well tolerated at all doses studied, supporting Neurocrine’s intentions to advance NBI- ‘568 into Phase 3 clinical trials in early 2025.
Neurocrine Biosciences | 03/09/2024 | By Aishwarya | 353
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy